The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Multidisciplinary management of cGvHD post HSCT
|
cGvHD is a complex condition affecting multiple organs, including the skin, liver, lungs, and eyes, leading to significant morbidity and mortality in patients undergoing HSCT.1 A review by Shah et al.1 published in Clinical Hematology International summarized the impact of cGvHD on patients, including those that are not captured in the National Institutes of Health Consensus Criteria. |
| Key learnings |
| cGvHD is a significant cause of mortality in patients post HSCT and the most common cause of NRM. cGvHD causes tissue damage, chronic inflammation, and organ fibrosis, impacting physical and emotional QoL. |
| Traditional management relies heavily on systemic glucocorticoids, but ECP or newer FDA-approved therapies like ibrutinib, ruxolitinib, and belumosudil provide options for patients with steroid-refractory cGvHD, improving outcomes. |
| Long-term use of immunosuppressants contributes to complications like osteoporosis, metabolic syndrome, cardiovascular disease, and endocrine dysfunction, necessitating careful monitoring and management. |
| Effective management of cGvHD requires a comprehensive and multidisciplinary care team approach, including transplant specialists, primary care providers, subspecialists, and allied health professionals to address treatment-related toxicities and to improve outcomes and QoL. |
Abbreviations: cGvHD, chronic graft-versus-host disease; ECP, extracorporeal photopheresis; FDA, U.S. Food and Drug Administration; HSCT, hematopoietic stem cell transplant; NRM, non-relapse mortality; QoL, quality of life.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content